Pharmacogenetic Markers to Predict the Clinical Response to Methotrexate in South Indian Tamil Patients with Psoriasis

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2017 Apr 27

PMID 28444425

Citations 18

Authors

S Indhumathi

Medha Rajappa

Laxmisha Chandrashekar

P H Ananthanarayanan

D M Thappa

V S Negi

Affiliations

Soon will be listed here.

Abstract

Introduction: Despite the advent of several new systemic therapies, methotrexate remains the gold standard for the treatment of moderate to severe psoriasis. However, there exists a significant heterogeneity in individual response to methotrexate. There are no consistently reliable markers to predict methotrexate treatment response till date.

Objectives: We aimed to demonstrate the association of certain genetic variants in the HLA (HLA-A2, HLA-B17, and HLA-Cw6) and the non-HLA genes including T-helper (Th)-1, Th-2, Th-17 cytokine genes (IFN-γ, IL-2, IL-4, IL-10, IL-12B, and IL-23R), and T-regulatory gene (FOXP3) with the methotrexate treatment response in South Indian Tamil patients with psoriasis.

Methods: Of the 360 patients recruited, 189 patients with moderate to severe psoriasis were treated with methotrexate. Of the 189 patients, 132 patients responded to methotrexate and the remaining 57 patients were non-responders. We analyzed the association of aforesaid polymorphisms with the methotrexate treatment outcome using binary logistic regression.

Results: We observed that there were significant differences between genotype frequencies of HLA-Cw6 and FOXP3 (rs3761548) among the responders compared to non-responders, with conservative estimation. We observed that pro-inflammatory cytokines such as IFN-γ, IL-2, IL-12, and IL-23 were markedly reduced with the use of methotrexate, in comparison to the baseline levels, while the plasma IL-4 levels were increased posttreatment.

Conclusion: Our results serve as preliminary evidence for the clinical use of genetic markers as predictors of response to methotrexate in psoriasis. This might aid in the future in the development of a point-of-care testing (POCT) gene chip, to predict optimal treatment response in patients with psoriasis, based on their individual genotypic profile.

Citing Articles

Mapping the psoriasis research landscape: A comprehensive bibliometric analysis from 2012-2023.

Garg S, Chawla M, Dixit M, Sharma A, Singh M, Singh V Int J Immunopathol Pharmacol. 2024; 38:3946320241290341.

PMID: 39393083 PMC: 11492216. DOI: 10.1177/03946320241290341.

Association of genetic variations in FoxP3 gene with Graves' disease in a Southwest Chinese Han population.

Tan G, Zheng G, Li J, Zhu Y, Liang Z, Li H Immun Inflamm Dis. 2023; 11(10):e1046.

PMID: 37904681 PMC: 10571500. DOI: 10.1002/iid3.1046.

, and : Predictive Biomarkers of Toxicity from Methotrexate Treatment in Patients Diagnosed with Moderate-to-Severe Psoriasis.

Membrive-Jimenez C, Vieira-Maroun S, Marquez-Pete N, Cura Y, Perez-Ramirez C, Tercedor-Sanchez J Biomedicines. 2023; 11(9).

PMID: 37761008 PMC: 10526923. DOI: 10.3390/biomedicines11092567.

Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine.

Berna-Rico E, Perez-Bootello J, Abbad-Jaime de Aragon C, Gonzalez-Cantero A Int J Mol Sci. 2023; 24(12).

PMID: 37372997 PMC: 10298473. DOI: 10.3390/ijms24129850.

Psoriatic Arthritis: Development, Detection and Prevention: A Scoping Review.

Kimak A, Robak E, Makowska J, Wozniacka A J Clin Med. 2023; 12(11).

PMID: 37298045 PMC: 10253876. DOI: 10.3390/jcm12113850.

References

Perrey C, Turner S, Pravica V, Howell W, Hutchinson I . ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol. 1999; 7(2):127-8. DOI: 10.1016/s0966-3274(99)80030-6. View

Julia M, Guilabert A, Lozano F, Suarez-Casasus B, Moreno N, Carrascosa J . The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA Dermatol. 2013; 149(9):1033-9. DOI: 10.1001/jamadermatol.2013.4632. View

Gerards A, de Lathouder S, de Groot E, Dijkmans B, Aarden L . Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford). 2003; 42(10):1189-96. DOI: 10.1093/rheumatology/keg323. View

Fichna M, Zurawek M, Fichna P, Ziolkowska-Suchanek I, Januszkiewicz D, Nowak J . Polymorphic variant at the IL2 region is associated with type 1 diabetes and may affect serum levels of interleukin-2. Mol Biol Rep. 2013; 40(12):6957-63. PMC: 3835945. DOI: 10.1007/s11033-013-2815-9. View

Ranganathan P . The challenges of methotrexate pharmacogenetics in rheumatoid arthritis. Pharmacogenomics. 2012; 13(4):377. DOI: 10.2217/pgs.12.13. View

Chiu H, Wang T, Chan C, Cheng Y, Lin S, Tsai T . Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol. 2014; 171(5):1181-8. DOI: 10.1111/bjd.13056. View

Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M . Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013; 169(2):458-63. DOI: 10.1111/bjd.12331. View

Gedebjerg A, Johansen C, Kragballe K, Iversen L . IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. Acta Derm Venereol. 2012; 93(2):150-5. DOI: 10.2340/00015555-1440. View

Miller S, Dykes D, Polesky H . A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16(3):1215. PMC: 334765. DOI: 10.1093/nar/16.3.1215. View

10.

Baker C, Mack A, Cooper A, Fischer G, Shumack S, Sidhu S . Treatment goals for moderate to severe psoriasis: an Australian consensus. Australas J Dermatol. 2013; 54(2):148-54. DOI: 10.1111/ajd.12014. View

11.

Vasilopoulos Y, Manolika M, Zafiriou E, Sarafidou T, Bagiatis V, Kruger-Krasagaki S . Pharmacogenetic analysis of TNF, TNFRSF1A, and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther. 2011; 16(1):29-34. DOI: 10.1007/BF03256427. View

12.

Warren R, Smith R, Campalani E, Eyre S, Smith C, Barker J . Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol. 2008; 128(8):1925-9. DOI: 10.1038/jid.2008.16. View

13.

Griffiths C, Christophers E, Barker J, Chalmers R, Chimenti S, Krueger G . A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007; 156(2):258-62. DOI: 10.1111/j.1365-2133.2006.07675.x. View

14.

Rebala K, Szczerkowska-Dobosz A, Niespodziana K, Wysocka J . Simple and rapid screening for HLA-Cw*06 in Polish patients with psoriasis. Clin Exp Dermatol. 2009; 35(4):431-6. DOI: 10.1111/j.1365-2230.2009.03627.x. View

15.

Cronstein B . Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005; 57(2):163-72. DOI: 10.1124/pr.57.2.3. View

16.

Elder J, Nair R, Henseler T, Jenisch S, Stuart P, Chia N . The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol. 2001; 137(11):1447-54. DOI: 10.1001/archderm.137.11.1447. View

17.

Langley R, Ellis C . Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004; 51(4):563-9. DOI: 10.1016/j.jaad.2004.04.012. View

18.

Elango T, Dayalan H, Gnanaraj P, Malligarjunan H, Subramanian S . Impact of methotrexate on oxidative stress and apoptosis markers in psoriatic patients. Clin Exp Med. 2013; 14(4):431-7. DOI: 10.1007/s10238-013-0252-7. View

19.

Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan P, Thappa D, Negi V . TNFAIP3 and TNIP1 polymorphisms confer psoriasis risk in South Indian Tamils. Br J Biomed Sci. 2016; 72(4):168-73. DOI: 10.1080/09674845.2015.11665748. View

20.

Elder J, Bruce A, Gudjonsson J, Johnston A, Stuart P, Tejasvi T . Molecular dissection of psoriasis: integrating genetics and biology. J Invest Dermatol. 2009; 130(5):1213-26. DOI: 10.1038/jid.2009.319. View